Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition

Bio-Rad (BIO) has been facing the impact of funding issues in the biopharmaceutical or BioPharma space, macroeconomic headwinds and competitive pressure. The stock carries a Zacks Rank #4 (Sell) currently.Since the beginning of 2023, Bio-Rad has been witnessing softness in smaller BioPharma companies, where historically, demand for life science products has been strong. This directly correlates with the funding constraints the broader pharmaceutical industry has started to experience. Management stated that ...